https://retacompare.com/news/retatrutide-outperforms-semaglutide-in-phase-3-a1c-and-weight-results 2026-10-29T06:33:45.000Z RetatrutideCompare en 2026-10-29T06:33:45.000Z Retatrutide Outperforms Semaglutide in Phase 3 A1C and Weight Results Clinical Trials, Retatrutide https://retacompare.com/news/retatrutide-shows-superior-a1c-weight-loss-over-semaglutide-in-trial 2026-10-28T22:40:25.000Z RetatrutideCompare en 2026-10-28T22:40:25.000Z Retatrutide Shows Superior A1C, Weight Loss Over Semaglutide in Trial Clinical Trials, Retatrutide https://retacompare.com/news/retatrutide-shows-superior-weight-loss-in-diabetes-compared-to-ozempic-in-trial 2026-10-28T19:51:26.000Z RetatrutideCompare en 2026-10-28T19:51:26.000Z Retatrutide Shows Superior Weight Loss in Diabetes Compared to Ozempic in Trial Clinical Trials, Retatrutide https://retacompare.com/news/retatrutide-outperforms-ozempic-in-direct-comparative-trial 2026-10-28T17:26:15.000Z RetatrutideCompare en 2026-10-28T17:26:15.000Z Retatrutide Outperforms Ozempic in Direct Comparative Trial Clinical Trials, Retatrutide https://retacompare.com/news/retatrutide-surpasses-ozempic-in-weight-loss-and-glucose-control-trial 2026-10-28T16:38:00.000Z RetatrutideCompare en 2026-10-28T16:38:00.000Z Retatrutide Surpasses Ozempic in Weight Loss and Glucose Control Trial Clinical Trials, Retatrutide https://retacompare.com/news/retatrutide-surpasses-ozempic-in-diabetes-trial-but-shows-more-side-effects 2026-10-28T15:53:00.000Z RetatrutideCompare en 2026-10-28T15:53:00.000Z Retatrutide Surpasses Ozempic in Diabetes Trial but Shows More Side Effects Clinical Trials, Retatrutide https://retacompare.com/news/potential-sleep-benefits-of-weight-loss-drug-explored 2026-10-28T11:00:59.000Z RetatrutideCompare en 2026-10-28T11:00:59.000Z Potential Sleep Benefits of Weight-Loss Drug Explored Weight Loss, Retatrutide https://retacompare.com/news/cagrisema-sustains-weight-loss-by-modulating-energy-dynamics-in-rats 2026-10-28T00:00:00.000Z RetatrutideCompare en 2026-10-28T00:00:00.000Z CagriSema Sustains Weight Loss by Modulating Energy Dynamics in Rats Weight Loss, Retatrutide https://retacompare.com/news/study-assesses-acmopatide-s-efficacy-in-type-1-diabetes-with-obesity 2026-10-28T00:00:00.000Z RetatrutideCompare en 2026-10-28T00:00:00.000Z Study Assesses Acmopatide's Efficacy in Type 1 Diabetes with Obesity Clinical Trials, Retatrutide https://retacompare.com/news/glp-1-agonists-role-in-diabetic-foot-management-explored 2026-10-28T00:00:00.000Z RetatrutideCompare en 2026-10-28T00:00:00.000Z GLP-1 Agonists' Role in Diabetic Foot Management Explored Clinical Trials, Retatrutide https://retacompare.com/news/tirzepatide-shows-significant-weight-loss-in-obesity-12-month-study 2026-10-28T00:00:00.000Z RetatrutideCompare en 2026-10-28T00:00:00.000Z Tirzepatide Shows Significant Weight Loss in Obesity: 12-Month Study Weight Loss, Retatrutide https://retacompare.com/news/glp-1-receptor-activation-may-reduce-chronic-migraine-symptoms 2026-10-28T00:00:00.000Z RetatrutideCompare en 2026-10-28T00:00:00.000Z GLP-1 Receptor Activation May Reduce Chronic Migraine Symptoms Clinical Trials, Retatrutide https://retacompare.com/news/survey-reveals-key-factors-influencing-glp-1-drug-satisfaction 2026-10-27T17:45:15.000Z RetatrutideCompare en 2026-10-27T17:45:15.000Z Survey Reveals Key Factors Influencing GLP-1 Drug Satisfaction Patient Experiences, Retatrutide https://retacompare.com/news/court-denies-novo-s-attempt-to-halt-lilly-s-obesity-drug-advertisements 2026-10-27T16:08:55.000Z RetatrutideCompare en 2026-10-27T16:08:55.000Z Court Denies Novo's Attempt to Halt Lilly's Obesity Drug Advertisements Market News, Retatrutide https://retacompare.com/news/glp-1-agonists-linked-to-reduced-kidney-failure-risk-in-obesity-ckd 2026-10-27T16:08:32.000Z RetatrutideCompare en 2026-10-27T16:08:32.000Z GLP-1 Agonists Linked to Reduced Kidney Failure Risk in Obesity, CKD Clinical Trials, Retatrutide https://retacompare.com/news/court-denies-novo-s-attempt-to-halt-lilly-s-obesity-drug-advertising 2026-10-27T16:03:00.000Z RetatrutideCompare en 2026-10-27T16:03:00.000Z Court Denies Novo's Attempt to Halt Lilly's Obesity Drug Advertising Market News, Retatrutide https://retacompare.com/news/concerns-about-glp-1s-for-weight-loss-highlighted-in-recent-report 2026-10-27T13:00:14.000Z RetatrutideCompare en 2026-10-27T13:00:14.000Z Concerns About GLP-1s for Weight Loss Highlighted in Recent Report Weight Loss, Retatrutide